Generated by AI
VolitionRx Limited is a multi-national epigenetics company focused on developing blood-based diagnostic tests for human and animal health. Its current product portfolio centers on the Nu.Q platform, which uses nucleosome-based biomarkers to help detect, monitor, and assess cancers and diseases associated with NETosis, including sepsis. The company also offers veterinary applications such as Nu.Q Vet and research tools such as Nu.Q Discover, alongside technologies designed to support earlier disease detection and treatment monitoring. VolitionRx Limited serves healthcare and life sciences markets across the United States, Europe, and Asia from its headquarters in Henderson, Nevada.
Website1489 West Warm Springs Road
Henderson, NV, 89014
United States
The latest articles about VNRX.
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2026. Volition management will host a conference call tomorrow, November 13 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.
Summary of Nov 13's posts. Generated by AI.
Summary of Aug 31's posts. Generated by AI.
Summary of Sep 17's posts. Generated by AI.
Summary of Sep 17's posts. Generated by AI.
Investors talking about VNRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.